Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Tenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' Opinion Survey
Tenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' Opinion Survey

NCT01322932

CompletedN/A

Sponsor: Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

Conditions: HIV Infection

Countries: Switzerland

The purpose of this study is to assess adherence, tolerability and satisfaction of each eligible HIV subjects switching from a two- or three-pill tenofovir-emtricitabine-efavirenz (TDF-FTC-EFV) to a one-pill TDF-FTC-EFV treatment.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* patients under TDF-FTC-EFV
* followed up at the Service of Infectious Disease of the University Hospital of Lausanne
* enrolled in the SHCS

Exclusion Criteria:

* patients receiving TDF-FTC-EFV in combination with other ARTs
* patients under TDF-FTC-EFV for less than 3 months
* patients not fluent in French
Locations (1)
  • Lausanne, Canton of Vaud, Switzerland